Remove barriers to clinical research for schedule 1 drugs with therapeutic potential

The authors argue that regulations governing clinical research on Schedule 1 drugs, which are classified as having high abuse potential and no accepted medical use, should be reassessed. They contend that such classification unnecessarily impedes scientific investigation into substances with therapeutic potential, such as certain psychedelics. The piece advocates for a review of the scheduling system to facilitate research that could lead to medical treatments, while maintaining appropriate controls to prevent misuse.

Study at a glance

Abstract

Regulation of clinical research on schedule 1 drugs with therapeutic potential should be reviewed, argue Leslie King, David Nutt and David Nichols